Key Takeaways
- Fianlimab, Regeneron’s investigational melanoma treatment, didn’t achieve its primary endpoint in a late-stage clinical trial competing with Merck’s Keytruda.
- The fianlimab plus Libtayo regimen failed to demonstrate statistically meaningful progression-free survival benefits.
- Shares of REGN plunged 11% to $618 during premarket hours after the trial results were announced.
- Several prominent analysts reduced price targets; Citi downgraded the stock to Neutral from Buy, cutting projections to $700 from $900.
- RBC Capital reduced its outlook to $707, noting the setback adds to mounting concerns about Regeneron’s development pipeline.
Shares of Regeneron Pharmaceuticals experienced a significant decline during Monday’s premarket session after the company disclosed disappointing results from a critical late-stage melanoma study.
Regeneron Pharmaceuticals, Inc., REGN
The biotechnology company’s shares tumbled 11% to $618 in early trading. The decline followed a late Friday announcement regarding the Phase 3 clinical trial outcomes.
The study evaluated fianlimab, an immunotherapy candidate for patients with advanced melanoma, administered alongside Regeneron’s approved cancer treatment Libtayo. This combination regimen was directly compared against Merck’s blockbuster cancer therapy Keytruda, which dominates the oncology market.
The clinical study included 1,546 participants divided into four treatment arms — a higher-dose combination, a lower-dose combination, Keytruda plus placebo, and Libtayo plus placebo.
The experimental drug failed to demonstrate statistically significant improvement in progression-free survival. Simply put, the treatment didn’t meaningfully extend the time before cancer worsened or patients died when compared to Keytruda.
While the higher-dose fianlimab-Libtayo combination showed numerical improvement versus Keytruda, the results failed to achieve statistical significance — the threshold required to confirm the findings weren’t due to chance.
The disappointing outcome triggered multiple analyst downgrades and reduced price forecasts across Wall Street.
Analyst Community Responds
Geoff Meacham from Citi Research downgraded Regeneron from Buy to Neutral while dramatically reducing his price target to $700 from $900. He emphasized that removing fianlimab from financial models eliminates “incremental positive catalysts” that would support a higher valuation.
Jefferies analyst Akash Tewari described the trial miss as “not particularly” unexpected, suggesting it confirms skeptical viewpoints. Despite maintaining a Buy recommendation, he decreased his price target to $870 from $890 and eliminated fianlimab projections from his forecasts.
RBC Capital adjusted its target downward to $707 from $762 while maintaining a Sector Perform stance. The investment firm had previously projected peak risk-adjusted revenue of $1.6–$1.8 billion for fianlimab in melanoma treatment — projections now completely erased.
Growing Development Portfolio Worries
RBC highlighted that the fianlimab disappointment represents part of a troubling trend. The firm referenced additional recent challenges including an unsuccessful itepekimab study, a less favorable regulatory approval for Eylea HD, and production complications.
Regenerons’s flagship eye drug Eylea experienced a 10% sales drop in the first quarter, which had already pressured the stock price earlier in the year. Truist Securities reduced its price projection to $769 due to regulatory postponements, though maintained a Buy stance citing better-than-anticipated Q1 financial results.
Not every analyst has adopted a pessimistic outlook. BofA Securities maintained a Buy recommendation with an $860 price objective despite the clinical setback. Jefferies similarly preserved its Buy rating.
On a brighter note, Dupixent — jointly developed with Sanofi — continues expanding into additional treatment areas and surpassing revenue forecasts. Eylea HD is reportedly stabilizing, and Regeneron’s balance sheet shows more cash reserves than outstanding debt obligations.
According to InvestingPro intelligence, thirteen analysts have lowered earnings projections for the company’s next reporting period.
